0 Replies
Copenhagen, 8th November 2005 Santaris Pharma, the Danish biopharmaceutical company developing innovative RNA-silencing drugs for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has approved an Investigational New Drug Application (IND) for the Company’s international Phase I/II study of SPC2996 in Chronic Lymphocytic Leukaemia... Contine Reading & Discuss→
0 Replies
Copenhagen, 3rd November 2005 Santaris Pharma, the Danish biopharmaceutical company developing innovative RNA-silencing drugs for the treatment of cancer, announced today that Keith McCullagh, President and Chief Executive Officer, will be presenting an overview of the company and progress in its product pipeline at the Rodman & Renshaw Techvest 7th... Contine Reading & Discuss→
